Dr. Giovanni Gaudino
The law firm Galiher DeRobertis Ono congratulates the Cancer Research Center of Hawaii (CRCH) for appointing a leading European mesothelioma expert, Dr. Giovanni Gaudino, as a Professor of Research. Cancer center director Dr. Michele Carbone, also a world renowned mesothelioma scientist, is excited about the arrival of Dr. Gaudino at the Center, one of 65 National Cancer Institute (NCI) designated institutions in our country.
Dr. Gaudino is a molecular biologist who studies how mesothelial cells become malignant and give rise to mesothelioma, a very aggressive cancer caused by asbestos exposure. His decision to bring his research to the U.S. is especially noteworthy because it gives much hope for developing new treatment therapies for mesothelioma patients in the United States. According to Dr. Carbone, Dr. Gaudino has applied his basic scientific findings to the development of some promising new treatments for mesothelioma that are currently being tested in clinical trials in Europe. Dr. Carbone says that he is “very happy that Giovanni will join CRCH” and he is “looking forward to working with him and with Dr. Haining Yang, Dr. Morris and the other mesothelioma experts at the Cancer Research Center.”
CRCH receives more federal grant funding for mesothelioma research than any other research institution in the U.S. The addition of Dr. Gaudino makes Carbone’s research team stronger. Together they “will find new ways to prevent and treat this terrible cancer,” says Dr. Carbone.
Born in Saronno in northern Italy, Giovanni Gaudino earned his M.S. (U.S. equivalent) in Biological Sciences and his Ph.D. (U.S. equivalent) in biochemistry from the University of Torino in northern Italy. Before accepting this position at the Cancer Research Center of Hawaii, Dr. Gaudino was a full professor of molecular biology in the School of Pharmacy and DISCAFF at the University of Piemonte Orientale ”A. Avogadro” in Novara, Italy.
Gaudino has been involved in a promising clinical trial in Italy involving the use of the combination drug therapy of Gleevec and Gemcitabine on mesothelioma patients. Attorney Gary Galiher commented that he was very excited about Dr. Gaudino’s appointment, both as a huge positive step for the Cancer Research Center of Hawaii, and more importantly for the progress it portends for mesothelioma treatment in our country.
